Objective: Early-onset obsessive-compulsive disorder (EOCD) and late-onset obsessivecompulsive disorder (LOCD) are distinct subtypes of obsessive-compulsive disorder (OCD).
Obsessive-compulsive disorder (OCD) is a common and disabling mental health condition, which is characterised by intrusive thoughts and related compulsive behaviours that are associated with significant levels of distress and interference (American Psychiatric Association, 2013) . The neurotransmitter serotonin plays a pivotal role in the pathology of this disorder, as supported by findings that a range of serotonin reuptake inhibitors (SRIs), from earlier SRIs such as tricyclic antidepressants (Fernandez Cordoba & Lopez-Ibor Alino, 1967) to later ones such as selective SRIs (SSRIs), have therapeutic efficacy in OCD.
Recent evidence suggests that early-onset (EOCD) and late-onset forms of OCD (LOCD) may be distinctive subgroups stemming from different neurological bases. Studies comparing them have found notable contrasts in a range of aspects, including familial aggregation (Nestadt et al., 2000) , comorbidity with tic disorder (Lochner & Stein, 2003; Millet et al., 2004; Rosario-Campos et al., 2001 ), symptom domains (Lochner & Stein, 2003; Millet et al., 2004; Tukel et al., 2005; Uguz, Askin, Cilli, & Besiroglu, 2006) , symptom severity (Lomax, Oldfield, & Salkovskis, 2009; Rosario-Campos et al., 2001) , and neuropsychological profiles (Hwang et al., 2007) . Several studies have also found that EOCD patients are less likely to respond to SRI pharmacotherapies (Ackerman, Greenland, Bystritsky, Morgenstern, & Katz, 1994; Lochner & Stein, 2003; Rosario-Campos et al., 2001 ) and that they took a longer time and had to have a greater number of drug trials to achieve the remission (Fontenelle, Mendlowicz, Marques, & Versiani, 2003) , although some reports found no difference in treatment response between groups (Uguz et al., 2006) . Previous molecular imaging studies on the serotonin transporter (SERT) have shown that OCD patients have lower SERT availability than controls (Matsumoto et al., 2010; Reimold et al., 2007) .
However, Hesse et al. (2011) reported that this is not the case for drug-naïve EOCD subgroup, showing that SERT availability is higher in drug-naïve EOCD than in LOCD. However, with SSRI treatment, SERT undergoes remodelling and relocalisation (Descarries & Riad, 2012) , and it is still unknown whether the difference in SERT availability between subgroups persists following pharmacotherapy with SSRI.
The main aim of this paper is to examine the difference in SERT availability between medicated EOCD and LOCD, by analysing the availability of SERT using in vivo neuroimaging. In this study, we used [ 11 C]DASB, a SERT-specific radioligand (Houle, Ginovart, Hussey, Meyer, & Wilson, 2000) , and escitalopram, one of the most serotonin-selective SSRI (Owens, Knight, & Nemeroff, 2001 ).
| METHODS
The protocol of this study was approved by the Institutional Review Board of Seoul National University Hospital, Seoul, Korea. All procedures in this study followed the recommendations of the Helsinki Declaration of 1975, as revised in 2008. The patients participated in the case-control study as described in Kim et al. (2016) , and this is a subgroup analysis report according to the age of onset.
Twelve male patients meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for OCD were enrolled from the outpatient clinic in Seoul National University Hospital. Six patients who had onset of OCD before age 17 were identified as EOCD patients, whereas the other six patients who had their disease after age 17 or later were regarded as LOCD patients. This threshold was consistent with most of the previous studies (Fontenelle et al., 2003; Hesse et al., 2011; Tukel et Compulsive Scale (YBOCS; Goodman et al., 1989) .
Because the patients were on maintenance therapy with escitalopram, drug-free SERT binding potential (BP) was calculated using two-compartmental pharmacokinetic modelling based on the measured plasma concentration of escitalopram, followed by an inhibitory I max pharmacodynamic modelling of which Kim et al. (2016) previously confirmed the validity in estimating the "baseline" drug-free BP. The primary regions of interest selected were putamen, caudate nucleus, thalamus, which consist of the cortico-striatothalamo-cortical loop (Pauls, Abramovitch, Rauch, & Geller, 2014) , and dorsal raphe nucleus (DRN), where serotonergic neurons are located. For the details on the pharmacokinetic-pharmacodynamic modelling processes, see the Supporting Information.
Statistical differences in drug-free SERT BP between EOCD and LOCD patients were examined by a Mann-Whitney U test. Pearson correlation analysis was used for the correlation between drug-free BP and age of onset, duration of illness, exposure to SSRIs, and YBOCS scores.
| RESULTS
The average (±standard deviation (SD)) age of illness onset was 13.0 ± 1.7 years for EOCD patients and 21.2 ± 2.7 years for LOCD patients, and it differed significantly between these subgroups of patients (U = 36, p = .002). Duration of illness (±SD), which equals to the age minus the age of onset, was 12.0 ± 6.4 for EOCD and 4.0 ± 2.5 years for LOCD patients and differed significantly between the groups (U = 2.5, p = .009). The escitalopram dose was 35.0 ± 20.7 mg for EOCD and 46.7 ± 18.6 mg for LOCD patients, which did not differ between groups (U = 24.5, p = .310). The mean age, duration of SSRI treatment, and the symptom severity also did not differ significantly between EOCD and LOCD patients (Table 1) .
Mean drug-free SERT BPs (±SD) of putamen, caudate nucleus, thalamus, and DRN estimated with the I max modelling were 1.88 ± 0.14, 1.08 ± 0.36, 1.49 ± 0.28, and 6.47 ± 0. 
| DISCUSSION
It has been consistently reported by PET studies using [ 11 C]DASB that OCD patients have lower SERT availability than controls (Matsumoto et al., 2010; Reimold et al., 2007) . Thus, higher SERT availability in EOCD than LOCD in key brain regions in drug-naïve patients (Hesse et al., 2011) suggests that EOCD patients may have less degree of serotonergic pathology. However, we report that the higher SERT availability in EOCD remained even after long-term SSRI treatment, which indicates that long-term pharmacotherapy may not affect the difference in serotonergic pathology between subgroups. In addition, the negative correlation between the drug-free BP and age of onset implies that the earlier OCD was developed, the less degree of serotonergic pathology there is. It may explain why EOCD patients have poorer treatment response on SRIs (Ackerman et al., 1994; Lochner & Stein, 2003; Rosario-Campos et al., 2001 ) and the more number of trials of pharmacotherapy (Fontenelle et al., 2003) . Thus, it can be also suggested that nonserotonergic treatments might be a better option than pharmacotherapy in treating EOCD patients, which is consistent with prior studies showing that OCD patients with comorbid tic disorder, whose onset is likely to be adolescence, respond better to dopaminergic pharmacotherapy such as antipsychotics (Bloch et al., 2006; McDougle et al., 1994) , further supporting the idea that EOCD patients may have different pathophysiology from LOCD, for example, the dopaminergic one.
We have found no correlation between the drug-free BP and YBOCS scores in either groups, whereas the majority of previous studies did not find any correlation (Matsumoto et al., 2010; Pogarell et al., 2003; Stengler-Wenzke, Muller, Angermeyer, Sabri, & Hesse, 2004; van der Wee et al., 2004) , and several others reported negative correlation between BP in key brain regions of OCD patients and their YBOCS scores (Hesse et al., 2005; Reimold et al., 2007; Zitterl et al., 2007) . A possible explanation for these inconsistent findings might be the heterogeneity of the target population, such as drug-naïve or drug-free patients, and imaging ligands used, such as [ 123 I]beta-CIT in previous studies.
The main limitation of this study is the small size of the sample.
We found statistically nonsignificant tendencies of higher drug-free BP in other key brain regions than the putamen, such as caudate nucleus and DRN in EOCD patients, and further studies with larger samples would help in clarifying such differences in those regions. In addition, pretreatment YBOCS score of the patients was not available, and hence, the difference of treatment response between groups could not be addressed in these data.
Notwithstanding the limitations, this study comes with several strengths. This is the first report studying medicated EOCD and LOCD patients, which enhances our knowledge of the contrasting pathophysiology between the subgroups, including treatment response to SRIs.
In addition, this study minimised bias using specific methods and population, such as the most selective SSRI, escitalopram as a drug (Owens et al., 2001 ), a highly SERT-selective ligand, [
11 C]DASB (Houle et al., 2000) , as a radioligand, and recruited OCD patients who were free of major comorbid disorders.
